Rituximab

被引：6
作者：
Doan, T [1 ]
Massarotti, E [1 ]
机构：
[1] Tufts Univ New England Med Ctr, Arthrit Treatment Ctr, Boston, MA 02111 USA
来源：
DRUGS OF TODAY | 2005年 / 41卷 / 12期
关键词：
D O I：
10.1358/dot.2005.41.12.953591
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Rituximab is a chimeric monoclonal antibody that targets the CD20 molecule on the B-cell surface. It is the first antibody of its kind to be licensed for the treatment of non-Hodgkin's lymphoma. Rituximab was found to be effective, well-tolerated and has a good safety profile, though its precise cellular effects are still not well understood. Rituximab has been shown to be of therapeutic benefit in various autoimmune diseases in which B lymphocytes play a role. This article summarizes the current literature regarding the use of rituximab in lymphoma, rheumatoid arthritis, systemic lupus erythematosus and other selected autoimmune diseases. (C) 2005 Prous Science. All rights reserved.
引用
收藏
页码：785 / 797
页数：13
相关论文
共 99 条
[1]  
ABUSHAKRA M, 1995, J RHEUMATOL, V22, P1259
[2]  
ALBERT D, 2004, ACR ARHP ANN SCI M S
[3]   EXPRESSION OF HUMAN B CELL-ASSOCIATED ANTIGENS ON LEUKEMIAS AND LYMPHOMAS - A MODEL OF HUMAN B-CELL DIFFERENTIATION [J].
ANDERSON, KC ;
BATES, MP ;
SLAUGHENHOUPT, BL ;
PINKUS, GS ;
SCHLOSSMAN, SF ;
NADLER, LM .
BLOOD, 1984, 63 (06) :1424-1433
[4]   Down-regulation of CD20 on B cells upon CD40 activation [J].
Anolik, J ;
Looney, RJ ;
Bottaro, A ;
Sanz, I ;
Young, F .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (09) :2398-2409
[5]   Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus [J].
Anolik, JH ;
Barnard, J ;
Cappione, A ;
Pugh-Bernard, AE ;
Felgar, RE ;
Looney, RJ ;
Sanz, I .
ARTHRITIS AND RHEUMATISM, 2004, 50 (11) :3580-3590
[6]   The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus [J].
Anolik, JH ;
Campbell, D ;
Felgar, RE ;
Young, F ;
Sanz, I ;
Rosenblatt, J ;
Looney, RJ .
ARTHRITIS AND RHEUMATISM, 2003, 48 (02) :455-459
[7]  
Arin MJ, 2005, EUR J DERMATOL, V15, P224
[8]   Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab) [J].
Arzoo, K ;
Sadeghi, S ;
Liebman, HA .
ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (10) :922-924
[9]  
Breedveld FC, 2005, ARTHRITIS RHEUM-US, V52, pS138
[10]   Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura [J].
Brændstrup, P ;
Bjerrum, OW ;
Nielsen, OJ ;
Jensen, BA ;
Clausen, NT ;
Hansen, PB ;
Andersen, I ;
Schmidt, K ;
Andersen, TM ;
Peterslund, NA ;
Birgens, HS ;
Plesner, T ;
Pedersen, BB ;
Hasselbalch, HC .
AMERICAN JOURNAL OF HEMATOLOGY, 2005, 78 (04) :275-280
12345678910